Search clinical trials for: potentially resectable

Total 1435 results

Zeng Jian

Recruiting

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Non Small Cell Lung Cancer

China
Zhiyong Huang

Not yet recruiting

Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Prospective, Single-arm, Multicenter Phase II Clinical Study of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Adebrelimab

China
Harbin Medical University

Not yet recruiting

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Cancer
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Xiangya Hospital of Central South University

Recruiting

Efficacy and Safety of NSCLC Patients With/Without Adjuvant Immunotherapy Who Have Achieved pCR After Neoadjuvant Immunotherapy

Resectable/Potentially Resectable NSCLC

China
Spanish Cooperative Group for the Treatment of...
Merck, S.L., Spain; Pierre Fabre Ibérica, S.A.

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Cetuximab in Combination With Encorafenib Plus Binimetinib as Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer (CEBBRA)

Colorectal Cancer
Sun Yat-sen University

Not yet recruiting

A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma

Potentially Resectable Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Geneplus-Beijing Co. Ltd.

Recruiting

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer (MRDinS3LC)

NSCLC

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
The First Affiliated Hospital with Nanjing Medical University; Fudan University and other collaborators

Not yet recruiting

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Pancreatic Carcinoma

China
Sun Yat-sen University
First People's Hospital of Foshan; The First Affiliated Hospital, Guangzhou... and other collaborators

Recruiting

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC (HAIC)

Hepatocellular Carcinoma | Chemotherapy Effect | Chemotherapeutic Toxicity

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC (Modified)

Biliary Tract Neoplasms
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Recruiting

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Pancreatic Cancer

United States
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

SIRT for Potentially Resectable HCC

Hepatocellular Carcinoma

China
M.D. Anderson Cancer Center

Recruiting

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Stage III Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Unrescetable Hepatocellular Carcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

Pancreatic Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III | Lung Adenocarcinoma Stage IV

China
Juan LI, MD

Recruiting

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Stage III Non-small Cell Lung Cancer

China
Fudan University

Not yet recruiting

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Hepatocellular Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Hunan Province Tumor Hospital

Recruiting

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Non Small Cell Lung Cancer

China
Shanghai Henlius Biotech

Not yet recruiting

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
Asan Medical Center

Recruiting

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Yonsei University

Recruiting

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Potentially Resectable Stage II/IIIa NSCLC

Korea, Republic of
Khon Kaen University

Recruiting

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Cholangiocarcinoma

Thailand
Sun Yat-sen University

Recruiting

TACE-HAIC vs. HAIC for Potentially Resectable HCC

Hepatocellular Carcinoma | Potentially Resection

China
Centre Hospitalier Universitaire de Besancon
Cancéropôle Grand-Est

Recruiting

Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable (Pancreas-CGE)

Pancreatic Cancer

France
The First Hospital of Jilin University

Active, not recruiting

Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer (Neo-Pre-IC)

IIIA Stage Non-small Cell Lung Cancer

China
Universitätsmedizin Mannheim
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Deutsche...

Active, not recruiting

Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Gastroesophageal Junction Adenocarcinoma

Germany
Technical University of Munich

Completed

Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction (MEMORI)

Adenocarcinoma of the Esophagogastric Junction

Germany
Yongchang Zhang

Completed

Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Shanghai Zhongshan Hospital

Active, not recruiting

Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Cancer | PD-1 Antibody | Lenvatinib | Gemox

China
Sun Yat-sen University
Innovent Biologics, Inc.

Active, not recruiting

HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC (HAICPD1-HCC)

Hepatocellular Carcinoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Completed

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III

China
Tianjin Medical University Cancer Institute and...

Active, not recruiting

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

China
The First Affiliated Hospital with Nanjing Medical...
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Hebei Medical University

Completed

Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction (A-C)

Gastroesophageal Junction Adenocarcinoma

China
Shanghai Zhongshan Hospital

Enrolling by invitation

Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Hepatocellular Carcinoma

China
Baylor Research Institute

Completed

Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer

Pancreatic Adenocarcinoma

United States
Celyad Oncology SA

Unknown

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases (SHRINK)

Colon Cancer Liver Metastasis

Belgium
Hebei Medical University

Completed

Perioperative Chemotherapy for Potentially Resectable Gastric Cancer

Gastric Cancer

China
Peking University
Taiho Pharmaceutical Co., Ltd.

Unknown

Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection

Advanced Gastric Carcinoma

China
Pancreatic Cancer Research Team
Celgene

Withdrawn

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Resectable Pancreatic Cancer
University of Texas Southwestern Medical Center

Terminated

Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Amer Zureikat

Completed

Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

Pancreatic Cancer

United States
Weijing Sun, MD, FACP

Withdrawn

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Adenocarcinoma | Stomach Cancer

United States
Institut Català d'Oncologia

Terminated

Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

Pancreatic Cancer

Spain

3

Subscribe